Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics. By combining groundbreaking exosome technology from well-renowned Oxford University and the Karolinska Institutet – the home of the Nobel Prize – we aim to revolutionise the treatment of a broad range of severe disease, with profound implications for human health. Based in Oxford, UK, Evox Therapeutics was founded in 2016 by Professor Matthew Wood of Oxford University, Assistant Professor Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institutet, to capitalise on foundational intellectual property springing from the groundbreaking exosome research carried out in these two world-leading labs. Backed by Oxford Sciences Innovation and with a driven multidisciplinary team, Evox is building an exosome powerhouse focusing on the development of a modular platform for clinical translation of a broad range of exosome-based therapeutics. Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.
Location: United Kingdom, England, Oxford
Employees: 51-200
Total raised: $144.58M
Founded date: 2016
Investors 5
| Date | Name | Website |
| - | Oxford Uni... | innovation... |
| - | OrbiMed | orbimed.co... |
| - | Panacea Ve... | panaceaven... |
| - | Oxford Sci... | oxfordscie... |
| - | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 19.02.2021 | Series C | $96.92M | - |
| 22.03.2019 | - | $1.98M | - |
| 03.09.2018 | Series B | $45.68M | - |
Mentions in press and media 17
| Date | Title | Description |
| 10.07.2024 | Antonin (Tony) de Fougerolles appointed as new Chair of etherna | Brings foundational experience in mRNA and LNP therapeutics given prior executive leadership roles at Moderna & Alnylam Will take an active role in expanding partnerships with biopharma Integrated partnership offering to customers remai... |
| 20.02.2021 | Daily funding roundup - February 20th, 2021 | Recogni has raised $48.9M; Photomath secured $23M; Torii landed $10M; Pipe17 picks up $8M Highland Electric Transportation: Highland Electric Transportation is a Hamilton, Ma.-based company that provides electric vehicles that are owned, po... |
| 19.02.2021 | Biotech startup Evox Therapeutics lands £69.2M | Evox Therapeutics has raised £69.2 million in a Series C led by Redmile Group. The British startup modifies exosomes to facilitate targeted drug delivery for severe diseases with limited treatment options. The new capital will be used to de... |
| 18.02.2021 | Evox Therapeutics Closes £69.2M Series C Financing | Evox Therapeutics Ltd, an Oxford, UK-based exosome therapeutics company, raised £69.2m ($95.4m) in Series C financing round. The round was led by Redmile Group with participatiom from new investors OrbiMed and Invus and existing investors O... |
| 18.02.2021 | Evox Therapeutics : completes £69.2 million Series C financing | OXFORD, England, Feb. 18, 2021 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, today announces that it has raised £69.2 million ($95.4 million) in a Series C financing round. The fina... |
| 18.02.2021 | EVOX THERAPEUTICS COMPLETES £69.2 MILLION SERIES C FINANCING | - |
| 18.01.2021 | John McHutchison joins the Board of Evox Therapeutics | OXFORD, England, Jan. 18, 2021 /PRNewswire/ -- Evox Therapeutics Ltd ("Evox" or the "Company"), a leading exosome therapeutics company, today announces that John McHutchison has joined its Board of Directors. John will b... |
| 25.03.2019 | Term Sheet — Monday, March 25 | FINANCIAL SNACKS Robinhood, a no-fee trading stock trading startup, just made its first acquisition, and it’s a millennial-focused media company called MarketSnacks. Paid Content What you need to know about growing cyberattacks From ExtraHo... |
| 22.03.2019 | Evox Therapeutics Secures £1.5M in Funding from Innovate UK | Evox Therapeutics, an Oxford, England, UK-based exosome therapeutics company, secured £1.5m in funding. Backers included Innovate UK, the UK’s Innovation Agency, through the Biomedical Catalyst Early Stage Award. The company intends to use ... |
| 04.09.2018 | Term Sheet — Tuesday, September 4 | IPO-BOUND Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop As Bloomberg notes, “Going first would allow Lyft to set expectations for ride-hailing companies, draw attention away fr... |
Show more